Dr. Lori M. Minasian

Dr. Visvanathan is a Professor on faculty at Johns Hopkins. She is a practicing medical oncologist and cancer epidemiologist focused on translating discoveries to the clinic and population as a whole. She directs the Clinical Cancer Genetics and Prevention service at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC) and is an active member of the Breast and Ovarian Program and Cancer Prevention and Control Program. Dr. Visvanathan is also Director of the Cancer Epidemiology Track in the Department of Epidemiology at Johns Hopkins Bloomberg School of Public Health. With her research centered on primary and secondary prevention of breast and ovarian cancer, her goal is to reduce the incidence of and mortality from breast cancer globally by conducting impactful studies at the local, national, and international levels. Specifically, she focuses on the identification of atrisk groups, potential biomarkers of risk and prognosis and evaluation of preventive agents across the continuum. She conducts both observational studies and early phase clinical trials. She also teaches and mentors the next generation of clinicians and cancer researchers. Dr. Visvanathan has also served on national committees focused on Breast Cancer Risk Reduction, Breast Cancer Genetics and Cancer Disparities. She has also co-chaired National Guidelines on Breast Cancer Endocrine Prevention. Locally, serving on the Maryland State Cancer Council. Dr. Visvanathan received her medical degree from the University of Sydney in Australia. She subsequently went on to complete training in internal medicine and medical oncology, including a period as chief resident at Royal Prince Alfred Hospital. She then did further training in Medical Oncology at Johns Hopkins and also obtained a master’s degree in clinical/cancer epidemiology at Johns Hopkins Bloomberg School of Public Health. This was followed by a postdoctoral fellow before coming on to faculty in both the Johns Hopkins School of Medicine and Bloomberg School of Public Health. Dr. Visvanathan is rated as a Distinguished provider by MediFind in the treatment of Menopause. Her top areas of expertise are Breast Cancer, Ovarian Cancer, Menopause, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.

Robert Reid is a Hematologist and an Oncologist in Fairfax, Virginia. Dr. Reid is rated as a Distinguished provider by MediFind in the treatment of Menopause. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Breast Cancer, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as a Distinguished provider by MediFind in the treatment of Menopause. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.